Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benjamin M Segal

Showing results (21-30 of 100) with videos related to

Pageof 10
Sort By:
Current Treatment Options in Neurology|April 24, 2013
B-cell targeting agents in the treatment of multiple sclerosisTiffany J Braley, Benjamin M Segal
Journal of Immunology (Baltimore, Md. : 1950)|July 9, 2005
Cutting edge: IL-12 induces CD4+CD25- T cell activation in the presence of T regulatory cellsIrah L King, Benjamin M Segal
Brain, Behavior, and Immunity|October 19, 2010
IL-23 modulated myelin-specific T cells induce EAE via an IFNγ driven, IL-17 independent pathwayMark A Kroenke, Benjamin M Segal
Journal of Neuroimmunology|July 8, 2010
Lymphoid chemokines in the CNSStephen J Lalor, Benjamin M Segal
European Journal of Immunology|July 23, 2013
Th1-mediated experimental autoimmune encephalomyelitis is CXCR3 independentStephen J Lalor, Benjamin M Segal
Proceedings of the National Academy of Sciences of the United States of America|March 12, 2016
Stable biomarker for plastic microgliaBenjamin M Segal, Roman J Giger
Current Opinion in Rheumatology|March 29, 2019
Treatment of neuromyelitis optica spectrum disordersAndrew R Romeo, Benjamin M Segal
Journal of Neuroimmunology|June 1, 2016
T-bet promotes the accumulation of encephalitogenic Th17 cells in the CNSHeather M Grifka-Walk, Benjamin M Segal
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 9, 2018
Americas Committee for Treatment and Research in Multiple Sclerosis Forum 2017: Environmental factors, genetics, and epigenetics in MS susceptibility and clinical courseBenjamin M Segal, Jeffrey A Cohen, Jack Antel
Frontiers in Immunology|August 1, 2024
Editorial: CNS myeloid cell function in health and diseaseChristian W Keller, Sarah Mundt, Benjamin M Segal
Pageof 10

Showing results (21-30 of 100) with videos related to

Sort By:
Pageof 10
Current Treatment Options in Neurology|April 24, 2013
B-cell targeting agents in the treatment of multiple sclerosisTiffany J Braley, Benjamin M Segal
Journal of Immunology (Baltimore, Md. : 1950)|July 9, 2005
Cutting edge: IL-12 induces CD4+CD25- T cell activation in the presence of T regulatory cellsIrah L King, Benjamin M Segal
Brain, Behavior, and Immunity|October 19, 2010
IL-23 modulated myelin-specific T cells induce EAE via an IFNγ driven, IL-17 independent pathwayMark A Kroenke, Benjamin M Segal
Journal of Neuroimmunology|July 8, 2010
Lymphoid chemokines in the CNSStephen J Lalor, Benjamin M Segal
European Journal of Immunology|July 23, 2013
Th1-mediated experimental autoimmune encephalomyelitis is CXCR3 independentStephen J Lalor, Benjamin M Segal
Proceedings of the National Academy of Sciences of the United States of America|March 12, 2016
Stable biomarker for plastic microgliaBenjamin M Segal, Roman J Giger
Current Opinion in Rheumatology|March 29, 2019
Treatment of neuromyelitis optica spectrum disordersAndrew R Romeo, Benjamin M Segal
Journal of Neuroimmunology|June 1, 2016
T-bet promotes the accumulation of encephalitogenic Th17 cells in the CNSHeather M Grifka-Walk, Benjamin M Segal
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 9, 2018
Americas Committee for Treatment and Research in Multiple Sclerosis Forum 2017: Environmental factors, genetics, and epigenetics in MS susceptibility and clinical courseBenjamin M Segal, Jeffrey A Cohen, Jack Antel
Frontiers in Immunology|August 1, 2024
Editorial: CNS myeloid cell function in health and diseaseChristian W Keller, Sarah Mundt, Benjamin M Segal
Pageof 10